Ensorcell (ensorcell.bio), a US-based company focused on reimaging life science tools and solutions for the biopharmaceutical industry, announced on Tuesday the appointments of Geoff Hodge and Amy Teachout to its senior leadership team.
Hodge is named head of Technology, responsible for accelerating high impact innovation across the company's technology and product development initiatives. He brings decades of experience spanning biopharmaceutical research, development, manufacturing, and technology leadership from his experience as co-founder of Xcellerex, CEO of SOTIO Biotech, and CTO of Unum Therapeutics. His focus at Ensorcell will be on translating novel concepts into scalable solutions that help partners advance programs efficiently from development through manufacturing.
Teachout has been appointed head of Customer Excellence, with responsibility for ensuring seamless, high-quality customer care across the full client engagement lifecycle. She brings extensive experience in program leadership, commercialisation support, logistics, and customer care.
Jeff Goldman, Ensorcell general manager, said: "Geoff and Amy bring deep industry expertise and complementary leadership strengths. Geoff's focus on accelerating high-impact breakthroughs and Amy's leadership in customer excellence directly support Ensorcell's mission to deliver meaningful, reliable outcomes for our biopharma partners."
Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market
FDA accepts rusfertide NDA and grants priority review for polycythemia vera
UAE approves PYRUKYND for treatment of thalassaemia
Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease
Genflow Biosciences receives first EUR336,467 tranche of EUR4m Wallonia grant
Atrium Therapeutics launches as newly independent, publicly traded company
Innovent Biologics' Jaypirca approved in China for new indication
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Neurizon Therapeutics doses first participant in NUZ-001 Regimen I HEALEY ALS Platform Trial
Melodia Therapeutics reports award of US patent covering MLD-151